On the stock market since 1996, it operates in the world of health and science. It has 108,165 employees. Now — the numbers.
This is an established company with proven profits.
That much dependence is a risk in itself: if this one line weakens, the whole company feels it directly.
No real growth (3% a year).
The gap is $9.2B. In times of high interest rates, a gap like that can squeeze a company.
angles, checked one by one.
The 2 that stand out are on screen; the rest came back neutral.
The council scores out of 10; report-card grades are out of 100.
Cost Efficiency: As sales grow, profit fails to keep the same pace.
The stock trades 41% below its peak. The market has trimmed its expectations for the company.
It met or beat analyst expectations in 7 of the last 8 quarters — consistency is a promise kept.
It pays out $0.86 per share each year — regular cash for whoever holds the stock.
Over the last 3 years, sales grew only 0% a year on average. At this size, speeding back up is not easy.
The stock trades 18% above the average analyst price target.
On our five-subject report card, FMS sits behind the class. A low grade doesn’t mean “doomed” — it means “big claim, small proof.”
The takeaway: FMS is an established business that has proven its profits for years. The real debate isn’t the quality of the business — it’s whether the price paid for the stock is too high.